%0 Journal Article
%T Short-term outcomes of a multicentre prospective study using a "visible" polyvinylidene fluoride onlay mesh for the prevention of midline incisional hernia.
%A Rodicio Miravalles JL
%A Méndez CSM
%A Lopez-Monclus J
%A Moreno Gijón M
%A López Quindós P
%A Amoza Pais S
%A López López A
%A García Bear I
%A Menendez de Llano Ortega R
%A Díez Pérez de Las Vacas MI
%A Garcia-Urena MA
%J Langenbecks Arch Surg
%V 409
%N 1
%D 2024 Apr 23
%M 38652308
%F 2.895
%R 10.1007/s00423-024-03307-x
%X BACKGROUND: Prophylactic meshes in high-risk patients prevent incisional hernias, although there are still some concerns about the best layer to place them in, the type of fixation, the mesh material, the significance of the level of contamination, and surgical complications. We aimed to provide answers to these questions and information about how the implanted material behaves based on its visibility under magnetic resonance imaging (MRI).
METHODS: This is a prospective multicentre observational cohort study. Preliminary results from the first 3 months are presented. We included general surgical patients who had at least two risk factors for developing an incisional hernia. Multivariate logistic regression was used. A polyvinylidene fluoride (PVDF) mesh loaded with iron particles was used in an onlay position. MRIs were performed 6 weeks after treatment.
RESULTS: Between July 2016 and June 2022, 185 patients were enrolled in the study. Surgery was emergent in 30.3% of cases, contaminated in 10.7% and dirty in 11.8%. A total of 5.6% of cases had postoperative wound infections, with the requirement of stoma being the only significant risk factor (OR = 7.59, p = 0.03). The formation of a seroma at 6 weeks detected by MRI, was associated with body mass index (OR = 1.13, p = 0.02).
CONCLUSIONS: The prophylactic use of onlay PVDF mesh in midline laparotomies in high-risk patients was safe and effective in the short term, regardless of the type of surgery or the level of contamination. MRI allowed us to detect asymptomatic seromas during the early process of integration.
BACKGROUND: This protocol was registered at ClinicalTrials.gov (NCT03105895).